{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:30:08Z","timestamp":1790281808476,"version":"4.1.0"},"reference-count":91,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T00:00:00Z","timestamp":1456099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0149610","type":"journal-article","created":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T14:11:06Z","timestamp":1456150266000},"page":"e0149610","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations"],"prefix":"10.1371","volume":"11","author":[{"given":"Neal","family":"Van Hoeven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharvari Waghmare","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghislain Ismael","family":"Nana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Bosco-Lauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Clements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Martyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Elliot","family":"Parks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea N.","family":"Coler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,2,22]]},"reference":[{"issue":"11","key":"ref1","first-page":"1399","article-title":"West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario","volume":"168","author":"C Pepperell","year":"2003","journal-title":"CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3201\/eid1202.050871","article-title":"Introductions of West Nile virus strains to Mexico","volume":"12","author":"E Deardorff","year":"2006","journal-title":"Emerging infectious diseases"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3201\/eid1210.060852","article-title":"West Nile virus isolation from equines in Argentina, 2006","volume":"12","author":"MA Morales","year":"2006","journal-title":"Emerging infectious diseases"},{"issue":"2","key":"ref4","first-page":"1","article-title":"Surveillance for human West Nile virus disease\u2014United States, 1999\u20132008","volume":"59","author":"NP Lindsey","year":"2010","journal-title":"Morbidity and mortality weekly report Surveillance summaries"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0950268812001070","article-title":"Estimated cumulative incidence of West Nile virus infection in US adults, 1999\u20132010","volume":"141","author":"LR Petersen","year":"2013","journal-title":"Epidemiology and infection"},{"key":"ref6","unstructured":"CDC. West Nile virus disease cases and deaths reported to CDC by year and clinical presentation, 1999\u20132014: Centers for Disease Control And Prevention; 2015. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.cdc.gov\/westnile\/statsmaps\/index.html\" xlink:type=\"simple\">http:\/\/www.cdc.gov\/westnile\/statsmaps\/index.html<\/ext-link>."},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1001\/jama.2013.8042","article-title":"West Nile virus: review of the literature","volume":"310","author":"LR Petersen","year":"2013","journal-title":"Jama"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3390\/v6020606","article-title":"Clinical manifestations and outcomes of West Nile virus infection","volume":"6","author":"JJ Sejvar","year":"2014","journal-title":"Viruses"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1586\/eri.13.34","article-title":"West Nile virus and kidney disease","volume":"11","author":"L Barzon","year":"2013","journal-title":"Expert review of anti-infective therapy"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/v6010013","article-title":"Replication cycle and molecular biology of the West Nile virus","volume":"6","author":"MA Brinton","year":"2014","journal-title":"Viruses"},{"issue":"23","key":"ref11","doi-asserted-by":"crossref","first-page":"11467","DOI":"10.1128\/JVI.01125-06","article-title":"Crystal structure of the West Nile virus envelope glycoprotein","volume":"80","author":"GE Nybakken","year":"2006","journal-title":"Journal of virology"},{"issue":"22","key":"ref12","doi-asserted-by":"crossref","first-page":"11000","DOI":"10.1128\/JVI.01735-06","article-title":"Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes","volume":"80","author":"R Kanai","year":"2006","journal-title":"Journal of virology"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1073\/pnas.0832193100","article-title":"A ligand-binding pocket in the dengue virus envelope glycoprotein","volume":"100","author":"Y Modis","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6529","key":"ref14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/375291a0","article-title":"The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution","volume":"375","author":"FA Rey","year":"1995","journal-title":"Nature"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.chom.2008.08.004","article-title":"Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development","volume":"4","author":"TC Pierson","year":"2008","journal-title":"Cell host & microbe"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1586\/14760584.2014.906309","article-title":"Current trends in West Nile virus vaccine development","volume":"13","author":"IJ Amanna","year":"2014","journal-title":"Expert review of vaccines"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.3390\/v5102384","article-title":"Vaccines in development against West Nile virus","volume":"5","author":"S Brandler","year":"2013","journal-title":"Viruses"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1128\/JVI.02903-12","article-title":"A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice","volume":"87","author":"AK Pinto","year":"2013","journal-title":"Journal of virology"},{"issue":"49","key":"ref19","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.1016\/j.vaccine.2007.09.055","article-title":"Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine","volume":"25","author":"I Samina","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.virol.2007.12.021","article-title":"Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine","volume":"374","author":"CK Lim","year":"2008","journal-title":"Virology"},{"issue":"19","key":"ref21","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1016\/j.vaccine.2010.02.092","article-title":"An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system","volume":"28","author":"KK Orlinger","year":"2010","journal-title":"Vaccine"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12985-015-0282-8","article-title":"The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys","volume":"12","author":"Y Muraki","year":"2015","journal-title":"Virology journal"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1086\/425933","article-title":"Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells","volume":"190","author":"M Qiao","year":"2004","journal-title":"The Journal of infectious diseases"},{"issue":"7","key":"ref24","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.vaccine.2013.12.030","article-title":"Matrix-M adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice","volume":"32","author":"SE Magnusson","year":"2014","journal-title":"Vaccine"},{"issue":"9","key":"ref25","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1128\/CVI.00119-09","article-title":"Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys","volume":"16","author":"MM Lieberman","year":"2009","journal-title":"Clinical and vaccine immunology: CVI"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.vaccine.2006.08.018","article-title":"Preparation and immunogenic properties of a recombinant West Nile subunit vaccine","volume":"25","author":"MM Lieberman","year":"2007","journal-title":"Vaccine"},{"issue":"9","key":"ref27","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.4049\/jimmunol.167.9.5273","article-title":"Immunization of mice against West Nile virus with recombinant envelope protein","volume":"167","author":"T Wang","year":"2001","journal-title":"Journal of immunology"},{"issue":"30","key":"ref28","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1016\/j.vaccine.2005.03.006","article-title":"A recombinant envelope protein vaccine against West Nile virus","volume":"23","author":"M Ledizet","year":"2005","journal-title":"Vaccine"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.4049\/jimmunol.1000768","article-title":"TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis","volume":"185","author":"SL Demento","year":"2010","journal-title":"Journal of immunology"},{"issue":"11","key":"ref30","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1086\/517613","article-title":"A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity","volume":"195","author":"WF McDonald","year":"2007","journal-title":"The Journal of infectious diseases"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1743-422X-7-146","article-title":"A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice","volume":"7","author":"G Spohn","year":"2010","journal-title":"Virology journal"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1743-422X-10-129","article-title":"A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies","volume":"10","author":"AJ Chua","year":"2013","journal-title":"Virology journal"},{"issue":"9","key":"ref33","doi-asserted-by":"crossref","first-page":"e108056","DOI":"10.1371\/journal.pone.0108056","article-title":"Protection of a single dose west nile virus recombinant subviral particle vaccine against lineage 1 or 2 strains and analysis of the cross-reactivity with Usutu virus","volume":"9","author":"T Merino-Ramos","year":"2014","journal-title":"PloS one"},{"issue":"9","key":"ref34","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1128\/JVI.75.9.4040-4047.2001","article-title":"West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays","volume":"75","author":"BS Davis","year":"2001","journal-title":"Journal of virology"},{"issue":"9","key":"ref35","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.micinf.2007.05.013","article-title":"Co-immunization with West Nile DNA and inactivated vaccines provides synergistic increases in their immunogenicities in mice","volume":"9","author":"T Ishikawa","year":"2007","journal-title":"Microbes and infection \/ Institut Pasteur"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.virol.2004.11.022","article-title":"West Nile premembrane-envelope genetic vaccine encoded as a chimera containing the transmembrane and cytoplasmic domains of a lysosome-associated membrane protein: increased cellular concentration of the transgene product, targeting to the MHC II compartment, and enhanced neutralizing antibody response","volume":"332","author":"A Anwar","year":"2005","journal-title":"Virology"},{"issue":"32","key":"ref37","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1016\/j.vaccine.2009.01.137","article-title":"Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII","volume":"27","author":"MP Ramanathan","year":"2009","journal-title":"Vaccine"},{"issue":"1\u20132","key":"ref38","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.virol.2006.07.038","article-title":"Immunogenicity of West Nile virus infectious DNA and its noninfectious derivatives","volume":"356","author":"A Seregin","year":"2006","journal-title":"Virology"},{"issue":"5","key":"ref39","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nbt1400","article-title":"Single-round infectious particles enhance immunogenicity of a DNA vaccine against West Nile virus","volume":"26","author":"DC Chang","year":"2008","journal-title":"Nature biotechnology"},{"issue":"18","key":"ref40","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1073\/pnas.1834270100","article-title":"DNA vaccine coding for the full-length infectious Kunjin virus RNA protects mice against the New York strain of West Nile virus","volume":"100","author":"RA Hall","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"37","key":"ref41","doi-asserted-by":"crossref","first-page":"6352","DOI":"10.1016\/j.vaccine.2011.04.116","article-title":"A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII","volume":"29","author":"A Schneeweiss","year":"2011","journal-title":"Vaccine"},{"issue":"29","key":"ref42","doi-asserted-by":"crossref","first-page":"10708","DOI":"10.1073\/pnas.1408677111","article-title":"Enhancement of protein expression by alphavirus replicons by designing self-replicating subgenomic RNAs","volume":"111","author":"DY Kim","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"ref43","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3201\/eid0812.020229","article-title":"Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model","volume":"8","author":"RB Tesh","year":"2002","journal-title":"Emerging infectious diseases"},{"issue":"3","key":"ref44","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","article-title":"Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses","volume":"28","author":"B Guy","year":"2010","journal-title":"Vaccine"},{"issue":"6","key":"ref45","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2746\/042516407X217416","article-title":"Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model","volume":"39","author":"MT Long","year":"2007","journal-title":"Equine veterinary journal"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0042-6822(03)00450-1","article-title":"Molecularly engineered live-attenuated chimeric West Nile\/dengue virus vaccines protect rhesus monkeys from West Nile virus","volume":"314","author":"AG Pletnev","year":"2003","journal-title":"Virology"},{"issue":"29","key":"ref47","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1016\/j.vaccine.2005.02.020","article-title":"Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge","volume":"23","author":"K Karaca","year":"2005","journal-title":"Vaccine"},{"issue":"11","key":"ref48","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2460\/ajvr.2004.65.1459","article-title":"Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses","volume":"65","author":"L Siger","year":"2004","journal-title":"American journal of veterinary research"},{"issue":"3","key":"ref49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/jgm.837","article-title":"A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus","volume":"8","author":"MC Iglesias","year":"2006","journal-title":"The journal of gene medicine"},{"issue":"12","key":"ref50","doi-asserted-by":"crossref","first-page":"e3973","DOI":"10.1371\/journal.pone.0003973","article-title":"Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine","volume":"3","author":"F Coutant","year":"2008","journal-title":"PloS one"},{"issue":"2","key":"ref51","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1086\/426824","article-title":"Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis","volume":"191","author":"P Despres","year":"2005","journal-title":"The Journal of infectious diseases"},{"issue":"2","key":"ref52","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/infdis\/jis328","article-title":"Measles vaccine expressing the secreted form of West Nile virus envelope glycoprotein induces protective immunity in squirrel monkeys, a new model of West Nile virus infection","volume":"206","author":"S Brandler","year":"2012","journal-title":"The Journal of infectious diseases"},{"issue":"6","key":"ref53","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.vaccine.2008.11.087","article-title":"Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01","volume":"27","author":"AV Iyer","year":"2009","journal-title":"Vaccine"},{"issue":"9","key":"ref54","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1128\/CVI.00070-07","article-title":"Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses","volume":"14","author":"J Schepp-Berglind","year":"2007","journal-title":"Clinical and vaccine immunology: CVI"},{"issue":"4","key":"ref55","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/vim.2000.13.401","article-title":"A live attenuated West Nile virus strain as a potential veterinary vaccine","volume":"13","author":"S Lustig","year":"2000","journal-title":"Viral immunology"},{"issue":"1","key":"ref56","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.virol.2004.09.014","article-title":"An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development","volume":"330","author":"G Yamshchikov","year":"2004","journal-title":"Virology"},{"issue":"4","key":"ref57","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.vaccine.2009.10.112","article-title":"Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus","volume":"28","author":"MC Whiteman","year":"2010","journal-title":"Vaccine"},{"issue":"47","key":"ref58","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1016\/j.vaccine.2008.08.064","article-title":"Attenuated West Nile viruses bearing 3&apos;SL and envelope gene substitution mutations","volume":"26","author":"L Yu","year":"2008","journal-title":"Vaccine"},{"issue":"5","key":"ref59","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1128\/JVI.80.5.2396-2404.2006","article-title":"A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha\/beta interferon induction and attenuates virus virulence in mice","volume":"80","author":"WJ Liu","year":"2006","journal-title":"Journal of virology"},{"issue":"2","key":"ref60","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.virol.2006.03.007","article-title":"A single amino acid substitution in the central portion of the West Nile virus NS4B protein confers a highly attenuated phenotype in mice","volume":"349","author":"JA Wicker","year":"2006","journal-title":"Virology"},{"issue":"6","key":"ref61","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.4269\/ajtmh.2010.09-0310","article-title":"Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection","volume":"82","author":"DG Widman","year":"2010","journal-title":"The American journal of tropical medicine and hygiene"},{"issue":"1","key":"ref62","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/infdis\/jiq003","article-title":"Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults","volume":"203","author":"R Biedenbender","year":"2011","journal-title":"The Journal of infectious diseases"},{"issue":"48","key":"ref63","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1016\/j.vaccine.2013.07.064","article-title":"The live attenuated chimeric vaccine rWN\/DEN4Delta30 is well-tolerated and immunogenic in healthy flavivirus-naive adult volunteers","volume":"31","author":"AP Durbin","year":"2013","journal-title":"Vaccine"},{"issue":"47","key":"ref64","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1016\/j.vaccine.2012.08.063","article-title":"Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults &gt;\/ = 50 years of age","volume":"30","author":"GH Dayan","year":"2012","journal-title":"Vaccine"},{"key":"ref65","unstructured":"Coller BA PV, Weeks-Levy C, Ogata S. United States patent application No.US20120141520 A1: Recombinant subunit West Nile virus vaccine for protection of human subjects. 2012."},{"issue":"12","key":"ref66","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"SG Reed","year":"2013","journal-title":"Nature medicine"},{"issue":"7","key":"ref67","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1586\/14760584.2013.811208","article-title":"The use of Toll-like receptor 7\/8 agonists as vaccine adjuvants","volume":"12","author":"JP Vasilakos","year":"2013","journal-title":"Expert review of vaccines"},{"key":"ref68","article-title":"Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer","author":"J Scheiermann","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"ref69","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1586\/14760584.2014.863715","article-title":"Recent progress concerning CpG DNA and its use as a vaccine adjuvant","volume":"13","author":"H Shirota","year":"2014","journal-title":"Expert review of vaccines"},{"issue":"10","key":"ref70","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.4049\/jimmunol.1002156","article-title":"Flagellin as an adjuvant: cellular mechanisms and potential","volume":"185","author":"SB Mizel","year":"2010","journal-title":"Journal of immunology"},{"issue":"3","key":"ref71","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.coi.2012.03.008","article-title":"Adjuvants for human vaccines","volume":"24","author":"CR Alving","year":"2012","journal-title":"Current opinion in immunology"},{"issue":"7","key":"ref72","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1586\/14760584.2013.811204","article-title":"Adjuvants containing natural and synthetic Toll-like receptor 4 ligands","volume":"12","author":"GC Ireton","year":"2013","journal-title":"Expert review of vaccines"},{"issue":"5","key":"ref73","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.4049\/jimmunol.178.5.2699","article-title":"Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection","volume":"178","author":"JH Chu","year":"2007","journal-title":"Journal of immunology"},{"issue":"1","key":"ref74","doi-asserted-by":"crossref","first-page":"e16333","DOI":"10.1371\/journal.pone.0016333","article-title":"Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant","volume":"6","author":"RN Coler","year":"2011","journal-title":"PloS one"},{"issue":"17","key":"ref75","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1073\/pnas.0601932103","article-title":"A live, attenuated recombinant West Nile virus vaccine","volume":"103","author":"TP Monath","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"44","key":"ref76","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1016\/j.vaccine.2014.08.051","article-title":"Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD)","volume":"32","author":"SJ Seligman","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"ref77","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/153036604773083004","article-title":"The epidemic of West Nile virus in the United States, 2002","volume":"4","author":"DR O'Leary","year":"2004","journal-title":"Vector borne and zoonotic diseases"},{"issue":"9130","key":"ref78","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(98)03538-7","article-title":"West Nile encephalitis epidemic in southeastern Romania","volume":"352","author":"TF Tsai","year":"1998","journal-title":"Lancet"},{"issue":"4","key":"ref79","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3201\/eid0704.017414","article-title":"Clinical characteristics of the West Nile fever outbreak, Israel, 2000","volume":"7","author":"MY Chowers","year":"2001","journal-title":"Emerging infectious diseases"},{"issue":"2","key":"ref80","doi-asserted-by":"crossref","first-page":"e88979","DOI":"10.1371\/journal.pone.0088979","article-title":"GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza","volume":"9","author":"CH Clegg","year":"2014","journal-title":"PloS one"},{"issue":"43","key":"ref81","doi-asserted-by":"crossref","first-page":"17585","DOI":"10.1073\/pnas.1207308109","article-title":"Adjuvant solution for pandemic influenza vaccine production","volume":"109","author":"CH Clegg","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"ref82","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.antiviral.2013.09.010","article-title":"Neurological approaches for investigating West Nile virus disease and its treatment in rodents","volume":"100","author":"JD Morrey","year":"2013","journal-title":"Antiviral Res"},{"issue":"6","key":"ref83","doi-asserted-by":"crossref","first-page":"955","DOI":"10.4269\/ajtmh.2008.79.955","article-title":"Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters","volume":"79","author":"MT Siirin","year":"2008","journal-title":"The American journal of tropical medicine and hygiene"},{"issue":"93","key":"ref84","doi-asserted-by":"crossref","first-page":"93ra69","DOI":"10.1126\/scitranslmed.3002135","article-title":"Targeting TLRs expands the antibody repertoire in response to a malaria vaccine","volume":"3","author":"SR Wiley","year":"2011","journal-title":"Science translational medicine"},{"issue":"23","key":"ref85","doi-asserted-by":"crossref","first-page":"13845","DOI":"10.1128\/JVI.02086-14","article-title":"Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination","volume":"88","author":"J Jarmer","year":"2014","journal-title":"Journal of virology"},{"issue":"18","key":"ref86","doi-asserted-by":"crossref","first-page":"10324","DOI":"10.1128\/JVI.00480-13","article-title":"An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody","volume":"87","author":"N Petrovsky","year":"2013","journal-title":"Journal of virology"},{"issue":"31","key":"ref87","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1016\/S0264-410X(03)00507-3","article-title":"Partial protective effect of inactivated Japanese encephalitis vaccine on lethal West Nile virus infection in mice","volume":"21","author":"T Takasaki","year":"2003","journal-title":"Vaccine"},{"issue":"10","key":"ref88","doi-asserted-by":"crossref","first-page":"e13677","DOI":"10.1371\/journal.pone.0013677","article-title":"A synthetic adjuvant to enhance and expand immune responses to influenza vaccines","volume":"5","author":"RN Coler","year":"2010","journal-title":"PloS one"},{"issue":"7","key":"ref89","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1089\/vbz.2009.0230","article-title":"West Nile virus lineage 2 as a cause of zoonotic neurological disease in humans and horses in southern Africa","volume":"10","author":"M Venter","year":"2010","journal-title":"Vector borne and zoonotic diseases"},{"issue":"1\u20132","key":"ref90","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.vetmic.2013.03.005","article-title":"Explosive spread of a neuroinvasive lineage 2 West Nile virus in Central Europe, 2008\/2009","volume":"165","author":"T Bakonyi","year":"2013","journal-title":"Veterinary microbiology"},{"issue":"4","key":"ref91","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3201\/eid1204.051379","article-title":"Lineage 1 and 2 strains of encephalitic West Nile virus, central Europe","volume":"12","author":"T Bakonyi","year":"2006","journal-title":"Emerging infectious diseases"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0149610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T18:51:20Z","timestamp":1588963880000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0149610"}},"subtitle":[],"editor":[{"given":"Matthias Johannes","family":"Schnell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,2,22]]},"references-count":91,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0149610","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,22]]}}}